Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Fingolimod Capsules in Healthy Adults
NCT05145621Phase 1Completed
- Sponsor
- Alembic Pharmaceuticals Ltd.
- Start
- Oct 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fingolimod in multiple sclerosis (MS) (2 arms), sponsored by Alembic Pharmaceuticals Ltd. Primary endpoints: Peak Plasma Concentration up to 72 hours and Area Under the Curve 0-72h. Started Oct 2015; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05145621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145621.